Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy.
Bacillus Calmette-Guerin
Lower urinary tract symptoms
Patient-reported outcome measures
Quality of life
Sleep
Urinary bladder neoplasms
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
11
05
2021
accepted:
25
07
2021
pubmed:
17
8
2021
medline:
15
12
2021
entrez:
16
8
2021
Statut:
ppublish
Résumé
We investigated sleep parameters and patient-reported outcomes before, during, and after induction Bacillus Calmette-Guerin therapy using questionnaires and actigraphy in patients with non-muscle invasive bladder cancer. We investigated 10 patients who received Bacillus Calmette-Guerin therapy once weekly for 8 weeks. The International Prostate Symptom Score, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, Functional Assessment of Cancer Therapy-Bladder, and multi-item Short Form-8 tools were used to assess patient-reported outcomes. Participants completed all questionnaires before (baseline), at the 4th and 8th doses, and 1 month after the last Bacillus Calmette-Guerin dose. The MotionWatch8 was fastened to patients' waist throughout the study. Composite sleep quality was determined based on sleep duration, efficiency, and fragmentation. We observed a transient increase in frequency/nocturia subscores and the insomnia subscore. The number of patients with poor sleep quality increased from 0 (0%) at baseline to 7 (70%) at the 4th dose and to 6 (60%) patients at the 8th dose. Among 10 patients, 6 (60%) were assigned to the sleep deterioration group and 4 (40%) to the non-deterioration group. Sleep quality was restored to baseline levels in 5 of 6 patients (83%) within 1 month after the last dose in the sleep deterioration group, and the nocturia subscore of the International Prostate Symptom Score was significantly increased only in this group (P=0.03). This is the first study that confirms intravesical Bacillus Calmette-Guerin-induced sleep quality deterioration based on a questionnaire survey and actigraphy.
Identifiants
pubmed: 34398288
doi: 10.1007/s00520-021-06468-3
pii: 10.1007/s00520-021-06468-3
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
887-895Subventions
Organisme : Japan Society for the Promotion of Science
ID : 21592057
Organisme : Japan Society for the Promotion of Science
ID : 16K20159
Organisme : Japan Society for the Promotion of Science
ID : 26861290
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
doi: 10.3322/caac.21492
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J et al (2019) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol 76:639–657
doi: 10.1016/j.eururo.2019.08.016
El Turabi A, Abel GA, Roland M, Lyratzopoulos G (2013) Variation in reported experience of involvement in cancer treatment decision making: evidence from the national cancer patient experience survey. Br J Cancer 109:780–787
doi: 10.1038/bjc.2013.316
Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S et al (2021) Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol 79:621–632
doi: 10.1016/j.eururo.2021.01.032
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R et al (2021) Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer 21:266
doi: 10.1186/s12885-021-07966-7
Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198:552–559
doi: 10.1016/j.juro.2017.04.086
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M et al (2020) Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27:702–709
doi: 10.1111/iju.14281
Blazeby JM, Hall E, Aaronson NK, Lloyd L, Waters R, Kelly JD et al (2014) Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 66:1148–1156
doi: 10.1016/j.eururo.2014.02.034
Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I et al (2013) The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol 190:857–862
doi: 10.1016/j.juro.2013.03.097
Siracusano S, Silvestri T, Bassi S, Porcaro AB, Cerruto MA, Talamini R et al (2018) Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol 25:9480–9485
pubmed: 30281005
Pesonen JS, Cartwright R, Vernooij RWM, Aoki Y, Agarwal A, Mangera A et al (2020) The impact of nocturia on mortality: a systematic review and meta-analysis. J Urol 203:486–495
doi: 10.1097/JU.0000000000000463
Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S et al (1998) A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34:810–815
doi: 10.1016/S0959-8049(97)00395-X
Degboe A, Ivanescu C, Rohay JM, Turner RR, Cella D (2019) Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients. Support Care Cancer 27:4189–4198
doi: 10.1007/s00520-019-04709-0
Tokuda Y, Okubo T, Ohde S, Jacobs J, Takahashi O, Omata F et al (2009) Assessing items on the SF-8 Japanese version for health-related quality of life: a psychometric analysis based on the nominal categories model of item response theory. Value Health 12:568–573
doi: 10.1111/j.1524-4733.2008.00449.x
Miyake M, Tanaka N, Asakawa I, Hori S, Morizawa Y, Tatsumi Y et al (2017) Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. BMC Urol 17:62
doi: 10.1186/s12894-017-0251-1
Kurinami N, Sugiyama S, Nishimura H, Morita A, Yoshida A, Hieshima K et al (2018) Clinical factors associated with initial decrease in body-fat percentage induced by add-on sodium-glucose co-transporter 2 inhibitors in patient with type 2 diabetes mellitus. Clin Drug Investig 38:19–27
doi: 10.1007/s40261-017-0580-6
Keage HA, Banks S, Yang KL, Morgan K, Brayne C, Matthews FE (2012) What sleep characteristics predict cognitive decline in the elderly? Sleep Med 13:886–892
doi: 10.1016/j.sleep.2012.02.003
Landry GJ, Best JR, Liu-Ambrose T (2015) Measuring sleep quality in older adults: a comparison using subjective and objective methods. Front Aging Neurosci 7:166
pubmed: 26441633
pmcid: 4561455
Rutherford C, Patel MI, Tait MA, Smith DP, Costa DSJ, Sengupta S et al (2021) Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. Qual Life Res 30:345–366
doi: 10.1007/s11136-020-02637-9
Thulin H, Kreicbergs U, Wijkström H, Steineck G, Henningsohn L (2010) Sleep disturbances decrease self-assessed quality of life in individuals who have undergone cystectomy. J Urol 184:198–202
doi: 10.1016/j.juro.2010.03.009
Hashim H, Blanker MH, Drake MJ, Djurhuus JC, Meijlink J, Morris V et al (2019) International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn 38:499–508
doi: 10.1002/nau.23917
Bonnet MH, Arand DL (2003) Clinical effects of sleep fragmentation versus sleep deprivation. Sleep Med Rev 7:297–3210
doi: 10.1053/smrv.2001.0245
Torimoto K, Hirayama A, Samma S, Yoshida K, Fujimoto K, Hirao Y (2009) The relationship between nocturnal polyuria and the distribution of body fluid: assessment by bioelectric impedance analysis. J Urol 181:219–224
doi: 10.1016/j.juro.2008.09.031
Olesen T, Paul J, Gramme P, Drake MJ, Vandewalle J, Everaert K (2020) Assessment of the most impactful combination of factors associated with nocturia and to define nocturnal polyuria by multivariate modelling. J Clin Med 9:2262
doi: 10.3390/jcm9072262
Tsuneki H, Sasaoka T, Sakurai T (2016) Sleep control, GPCRs, and glucose metabolism. Trends Endocrinol Metab 27:633–642
doi: 10.1016/j.tem.2016.06.011
Cheng TC, Lee YH, Chang YP, Lee DC (2020) Improved urinary melatonin level as the perspective indicator that leads to better sleeping quality in bladder cancer patients. Ther Adv Urol 12:1756287220940870
doi: 10.1177/1756287220940870
Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E et al (2008) Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 100:898–905
doi: 10.1093/jnci/djn171
Liu S, Madu CO, Lu Y (2018) The role of melatonin in cancer development. Oncomedicine 3:37–47
doi: 10.7150/oncm.25566
Chen YT, Yang CC, Shao PL, Huang CR, Yip HK (2019) Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway. J Pineal Res 66:e12536
doi: 10.1111/jpi.12536